PTCB Guide to SERMs

Also called selective estrogen receptor modulators · suffix -ifene · updated August 7, 2026

What gets tested

• Recognizing the -ifene suffix and matching brand to generic (Soltamox is tamoxifen, Evista is raloxifene)
• The tissue-selective concept, which is the whole point of the class
• Why tamoxifen carries a uterine cancer warning and raloxifene does not
• The blood clot risk shared by both agents
• The CYP2D6 interaction: strong inhibitors such as paroxetine and fluoxetine reduce tamoxifen's activation
• Which agent is used mainly for breast cancer and which mainly for osteoporosis

What is not tested

You are not asked to stage breast cancer, select adjuvant therapy, or interpret receptor status beyond the basic idea that these drugs act on the estrogen receptor. Concentrate on the suffix, the brand and generic pairs, the tissue-selective principle, the warnings, and the counseling points. Strengths, dosage forms, routes, special handling, and duration of therapy fall under PTCE knowledge area 1.4 and remain testable.

Why serms matter

SERMs are the cleanest illustration on the whole exam of a drug whose effect depends on the tissue rather than the molecule, which makes them a favourite conceptual question. They also carry serious, specific warnings that a technician needs to recognize, and tamoxifen's CYP2D6 interaction is a genuine, frequently encountered clinical problem because the interacting drugs are common antidepressants.

SERMs at a glance

Mechanism of action

The estrogen receptor does not work alone. When estrogen binds it, the receptor changes shape and then recruits helper proteins called coactivators or corepressors, and it is the balance of those helpers, which differs from tissue to tissue, that decides whether the gene is switched on or off. A selective estrogen receptor modulator exploits this. It binds the receptor and forces a shape that recruits corepressors in some tissues and coactivators in others, so the very same molecule behaves as an antagonist in one organ and an agonist in another. Tamoxifen is the classic example. In breast tissue it acts as an antagonist, blocking the estrogen signal that hormone receptor positive breast cancer cells depend on to grow, which is why it is central to treating and preventing that disease. In the uterus, however, it behaves as a weak agonist, stimulating the endometrium, which is why long-term use raises the risk of endometrial hyperplasia and uterine cancer. It also acts as an agonist in bone, which preserves bone density, and it raises clotting risk through effects on the liver. Raloxifene shifts the profile: it is an antagonist in both breast and uterus while remaining an agonist in bone, which is why it is used for osteoporosis and breast cancer risk reduction without carrying tamoxifen's uterine warning. Tamoxifen adds one further wrinkle: it is a prodrug that must be converted by the liver enzyme CYP2D6 into endoxifen, the metabolite that does most of the work. Strong CYP2D6 inhibitors, which include the antidepressants paroxetine and fluoxetine, can blunt that conversion and reduce the drug's effectiveness, so the pairing is generally avoided.

Common and important side effects

• Hot flashes and night sweats, which are the most common complaint with both agents
• Leg cramps
• Deep vein thrombosis and pulmonary embolism, appearing in boxed warnings for both drugs
• Endometrial hyperplasia and uterine cancer with tamoxifen, which raloxifene does not carry
• Stroke risk, which appears in the boxed warning for raloxifene and for tamoxifen in the risk-reduction setting
• Vaginal discharge, dryness, or bleeding
• Cataracts and other eye changes with long-term tamoxifen
• Nausea and fatigue

Key interactions

• Strong CYP2D6 inhibitors such as paroxetine, fluoxetine, and bupropion reduce the conversion of tamoxifen to its active metabolite and may reduce its effectiveness
• Warfarin's effect is increased by tamoxifen, raising bleeding risk, so INR is monitored closely
• Estrogen products oppose the intended effect and are generally not combined
• Other drugs that raise clot risk add to the thrombotic warning
• Cholestyramine reduces raloxifene absorption
• Aromatase inhibitors are generally not combined with tamoxifen, since they act on the same pathway differently

Patient counseling notes

• Report leg pain, swelling, warmth, or redness, and any sudden shortness of breath or chest pain, because these can signal a blood clot
• Report any abnormal vaginal bleeding promptly if taking tamoxifen, and keep gynecological check-ups
• Expect hot flashes, which are common and often ease over time
• Tell the pharmacist about any antidepressant, because some reduce tamoxifen's effectiveness
• Raloxifene is usually stopped before and during prolonged immobilization such as major surgery or bed rest, because sitting still raises clot risk
• Report sudden vision changes
• Take the medicine consistently: these are long-term therapies where adherence over years is what delivers the benefit

Practice questions

Work the SERMs questions below first, then widen out. Two skills carry most of the Medications domain, and each has its own quiz. The first is drug class identification: recognising which class a drug belongs to from its name or its stem, which is what the drug class identification quiz drills across every class. The second is brand and generic recall, because the exam switches between the two names freely and expects you to follow. Pair this guide with the brand and generic quiz until the brand and generic pairs in the table above come back without effort.

Related drug-class guides

Official sources

• MedlinePlus: Tamoxifen
• MedlinePlus: Raloxifene
• MedlinePlus: Osteoporosis (topic overview)

PTCB Quiz Prep is an independent study resource, not affiliated with the Pharmacy Technician Certification Board. This guide is for exam preparation, not medical advice. Part of the PTCB Medications domain.